Perrigo Sets 2026 All-In Adjusted EPS Outlook at $2.25 to $2.45
Perrigo Company plc set its 2026 adjusted diluted EPS outlook at $2.25 to $2.45, excluding its infant formula unit, which it classified as discontinued operations. Core EPS is expected at $2.15 to $2.35, with core sales declining 2.5% to 3.6% and an adjusted operating margin of 14% to 15%. The company plans to sell the unit to MeridianMade for up to $175 million, with $40 million upfront.
How this was made
The 30-second read
Why it matters
The guidance cut and divestiture are likely to depress the stock in the short term, but the cash proceeds and margin improvement could be positive over a longer horizon.
Market read
First‑report of a material guidance revision and a $175M transaction; relevant for health‑care equity traders.
What to watch
Performance‑based earn‑out up to $135M could boost long‑term returns if the unit recovers.
Background
Perrigo, a global consumer‑health company, is simplifying operations by exiting infant formula, a segment that has been cash‑intensive.
Ticker impact
Perrigo announced 2026 adjusted EPS outlook of $2.25‑$2.45 and a $175M sale of its infant formula unit, providing fresh guidance and a sizable divestiture.
likely downside as the market prices in reduced sales and margin pressure
The new EPS range is below prior expectations and the divestiture signals a retreat from a cash‑draining segment.
Market effects
Signals potential consolidation in the consumer health sector as peers may reassess infant formula exposure.
European consumer softness highlighted; may affect other consumer‑health firms with EU exposure.
Limited to health‑care investors; no broad market effect.
Counterpoint
The sale could free cash for strategic acquisitions, offering upside if the market overreacts to the guidance cut.
Key entities
- companyPerrigo Company plc
Issuer of the guidance and divestiture announcement.
- companyMeridianMade
Buyer of the infant formula unit.
